Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.42 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | DPP4 | P27487 | 1/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17025680 | 0.76 | LMNA (0.40) | KMT2ALMNASMN1; SMN2KDM4ERCE1 | |
| SCHEMBL6532206 | 0.73 | KDM4E (0.49) | KMT2ALMNASMN1; SMN2KDM4ERCE1 | |
| SCHEMBL26169830 | 0.69 | KMT2A (0.42) | KMT2ALMNASMN1; SMN2KDM4ERCE1 | |
| SCHEMBL24735865 | 0.69 | IL1R1 (0.44) | KMT2ALMNASMN1; SMN2KDM4ERCE1 | |
| SCHEMBL7419183 | 0.66 | ALDH1A1 (0.45) | KMT2ALMNASMN1; SMN2KDM4ERCE1 | |
| SCHEMBL13060362 | 0.65 | ALDH1A1 (0.54) | KMT2ALMNASMN1; SMN2KDM4EGAA | |
| SCHEMBL2118514 | 0.64 | HSP90AA1 (0.39) | KMT2ALMNASMN1; SMN2KDM4ERCE1 | |
| SCHEMBL257566 | 0.64 | GPR3 (0.52) | KMT2ALMNASMN1; SMN2KDM4EGAA | |
| SCHEMBL3396642 | 0.63 | ALDH1A1 (0.37) | LMNASMN1; SMN2KDM4EMAPK14ALDH1A1 | |
| SCHEMBL5332174 | 0.63 | KMT2A (0.67) | KMT2ALMNASMN1; SMN2KDM4ERCE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9464055-B2 | Quinoline derivatives useful as CB-1 inverse agonists | JANSSEN PHARMACEUTICA NV (BE) | 2016-10-11 | — | — | US | disclosed |
| US-20150239845-A1 | QUINOLINE DERIVATIVES USEFUL AS CB-1 INVERSE AGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2015-08-27 | — | — | US | disclosed |
| US-20150239844-A1 | QUINOLINE DERIVATIVES USEFUL AS CB-1 INVERSE AGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2015-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150239844-A1 | QUINOLINE DERIVATIVES USEFUL AS CB-1 INVERSE AGONISTS | CNR1, CNR2, GPR119 | KMT2A 3398/4885LMNA 3459/4885SMN1; SMN2 2701/4885 |
| US-20150239845-A1 | QUINOLINE DERIVATIVES USEFUL AS CB-1 INVERSE AGONISTS | CNR1, CNR2, GPR119 | KMT2A 3398/4885LMNA 3459/4885SMN1; SMN2 2701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.